Discover why combining simvastatin and rifaximin does not offer a clinically meaningful advantage in preventing severe ...

Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices ...

Can-Fite BioPharma (CANF) announced a significant clinical development: the disappearance of episodes of decompensated liver cirrhosis ...

Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030 Ramat Gan, Israel, Feb.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Discover a study in which non-selective β-blockers have demonstrated significant potential in preventing decompensation.

Cirrhosis is a condition in which scar tissue gradually replaces your healthy liver cells. It usually happens over a long period, often due to hepatitis, alcohol use disorder, or metabolic ...

Changes like fibrosis, or scarring of the tissue in the liver, may lead to cirrhosis. “Liver inflammation is common and can be related to many causes that are not serious,” says Meaghan M.

Age >56, shock, Model for End-Stage Liver Disease score >15, endoscopic+drug treatment and HE at admission were independent factors of death in high-risk patients. Conclusion pTIPS is associated with ...

prevention of liver injury following hypovolaemic shock and preventing/delaying progression of cirrhosis of any aetiology. Moreover, statins have been shown to have potential beneficial effects in the ...

However, where it fell short was with respect to the failure at week 36 with the phase 2b SYMMETRY study, which used EFX to treat compensated cirrhosis ... build up in the liver.